641 related articles for article (PubMed ID: 23231310)
1. Pretreatment patient-specific IMRT quality assurance: a correlation study between gamma index and patient clinical dose volume histogram.
Stasi M; Bresciani S; Miranti A; Maggio A; Sapino V; Gabriele P
Med Phys; 2012 Dec; 39(12):7626-34. PubMed ID: 23231310
[TBL] [Abstract][Full Text] [Related]
2. Initial experience of ArcCHECK and 3DVH software for RapidArc treatment plan verification.
Infusino E; Mameli A; Conti R; Gaudino D; Stimato G; Bellesi L; D'Angelillo RM; Ramella S; Benassi M; Trodella L
Med Dosim; 2014; 39(3):276-81. PubMed ID: 25088815
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the accuracy of 3DVH software estimates of dose to virtual ion chamber and film in composite IMRT QA.
Olch AJ
Med Phys; 2012 Jan; 39(1):81-6. PubMed ID: 22225277
[TBL] [Abstract][Full Text] [Related]
4. Breaking bad IMRT QA practice.
Stojadinovic S; Ouyang L; Gu X; Pompoš A; Bao Q; Solberg TD
J Appl Clin Med Phys; 2015 May; 16(3):5242. PubMed ID: 26103484
[TBL] [Abstract][Full Text] [Related]
5. Moving from gamma passing rates to patient DVH-based QA metrics in pretreatment dose QA.
Zhen H; Nelms BE; Tome WA
Med Phys; 2011 Oct; 38(10):5477-89. PubMed ID: 21992366
[TBL] [Abstract][Full Text] [Related]
6. VMAT QA: measurement-guided 4D dose reconstruction on a patient.
Nelms BE; Opp D; Robinson J; Wolf TK; Zhang G; Moros E; Feygelman V
Med Phys; 2012 Jul; 39(7):4228-38. PubMed ID: 22830756
[TBL] [Abstract][Full Text] [Related]
7. Tomotherapy treatment plan quality assurance: the impact of applied criteria on passing rate in gamma index method.
Bresciani S; Di Dia A; Maggio A; Cutaia C; Miranti A; Infusino E; Stasi M
Med Phys; 2013 Dec; 40(12):121711. PubMed ID: 24320497
[TBL] [Abstract][Full Text] [Related]
8. Correlation between gamma index passing rate and clinical dosimetric difference for pre-treatment 2D and 3D volumetric modulated arc therapy dosimetric verification.
Jin X; Yan H; Han C; Zhou Y; Yi J; Xie C
Br J Radiol; 2015 Mar; 88(1047):20140577. PubMed ID: 25494412
[TBL] [Abstract][Full Text] [Related]
9. 3D DVH-based metric analysis versus per-beam planar analysis in IMRT pretreatment verification.
Carrasco P; Jornet N; Latorre A; Eudaldo T; Ruiz A; Ribas M
Med Phys; 2012 Aug; 39(8):5040-9. PubMed ID: 22894429
[TBL] [Abstract][Full Text] [Related]
10. Biological consequences of MLC calibration errors in IMRT delivery and QA.
Moiseenko V; Lapointe V; James K; Yin L; Liu M; Pawlicki T
Med Phys; 2012 Apr; 39(4):1917-24. PubMed ID: 22482613
[TBL] [Abstract][Full Text] [Related]
11. Per-beam, planar IMRT QA passing rates do not predict clinically relevant patient dose errors.
Nelms BE; Zhen H; Tomé WA
Med Phys; 2011 Feb; 38(2):1037-44. PubMed ID: 21452741
[TBL] [Abstract][Full Text] [Related]
12. A new metric for assessing IMRT modulation complexity and plan deliverability.
McNiven AL; Sharpe MB; Purdie TG
Med Phys; 2010 Feb; 37(2):505-15. PubMed ID: 20229859
[TBL] [Abstract][Full Text] [Related]
13. Using a novel dose QA tool to quantify the impact of systematic errors otherwise undetected by conventional QA methods: clinical head and neck case studies.
Chan MF; Li J; Schupak K; Burman C
Technol Cancer Res Treat; 2014 Feb; 13(1):57-67. PubMed ID: 23819494
[TBL] [Abstract][Full Text] [Related]
14. Retrospective dosimetry study of intensity-modulated radiation therapy for nasopharyngeal carcinoma: measurement-guided dose reconstruction and analysis.
Sun WZ; Zhang DD; Peng YL; Chen L; Kang DH; Wang B; Deng XW
Radiat Oncol; 2018 Mar; 13(1):42. PubMed ID: 29544512
[TBL] [Abstract][Full Text] [Related]
15. Predicting dose-volume histograms for organs-at-risk in IMRT planning.
Appenzoller LM; Michalski JM; Thorstad WL; Mutic S; Moore KL
Med Phys; 2012 Dec; 39(12):7446-61. PubMed ID: 23231294
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity of volumetric modulated arc therapy patient specific QA results to multileaf collimator errors and correlation to dose volume histogram based metrics.
Coleman L; Skourou C
Med Phys; 2013 Nov; 40(11):111715. PubMed ID: 24320423
[TBL] [Abstract][Full Text] [Related]
17. IMRT quality assurance using a second treatment planning system.
Anjum MN; Parker W; Ruo R; Aldahlawi I; Afzal M
Med Dosim; 2010; 35(4):274-9. PubMed ID: 19944590
[TBL] [Abstract][Full Text] [Related]
18. Commissioning and quality assurance of a commercial stereotactic treatment-planning system for extracranial IMRT.
Wang L; Li J; Paskalev K; Hoban P; Luo W; Chen L; McNeeley S; Price R; Ma C
J Appl Clin Med Phys; 2006; 7(1):21-34. PubMed ID: 16518314
[TBL] [Abstract][Full Text] [Related]
19. Quantitative evaluation of 3D dosimetry for stereotactic volumetric-modulated arc delivery using COMPASS.
Vikraman S; Manigandan D; Karrthick KP; Sambasivaselli R; Senniandavar V; Ramu M; Rajesh T; Lutz M; Muthukumaran M; Karthikeyan N; Tejinder K
J Appl Clin Med Phys; 2014 Jan; 16(1):5128. PubMed ID: 25679152
[TBL] [Abstract][Full Text] [Related]
20. Clinically relevant quality assurance (QA) for prostate RapidArc plans: gamma maps and DVH-based evaluation.
Cozzolino M; Oliviero C; Califano G; Clemente S; Pedicini P; Caivano R; Chiumento C; Fiorentino A; Fusco V
Phys Med; 2014 Jun; 30(4):462-72. PubMed ID: 24480527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
